Stock Chart

CHRS

$1.01 -3.81%
Score: 57.2 HOLD
Pro
Screener
Vol: 0.45x (vs SPY: 0.5x | vs QQQ: 0.5x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 23, 2026
Bear Pennant Bearish scenario quality 62/100
Setup invalidates on a close above $1.05 · pole −24% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About CHRS - Coherus Oncology, Inc. Common Stock

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio …

Key Statistics

Market Cap $162M

This CHRS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track CHRS's price movements with trendlines, gamma walls, and key support/resistance levels.